Comprehensive Analysis of Tirzepatide Access Options as Resolution Season Peaks: MyStart Health Programs, FDA Context, Coverage Developments, and Questions to Consider Before Starting GLP-1 ...

A comprehensive mini-review published today after peer review in Brain Medicine by Dr. Tao Ma and colleagues at Wake Forest ...

Europe needs a new system compelling researchers, governments and companies to share risk from the earliest stages of therapy ...

Obesity and diabetes treatment is undergoing a revolution with the advent of GLP-1 drugs, which help manage weight, control ...

Lurking in the vast expanse of the ocean and buried deep in the Siberian permafrost, there are giants—not blue whales and ...

Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it picked up a year ago, was hit with a warning letter from the FDA last month. The ...

After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making history again with the first FDA approval of a GLP-1 pill for weight loss.

Novo Nordisk first to market with Wegovy pill Analysts see potential but question if pills are a 'game changer' Advantage for Novo could be short-lived, analysts say The approval of Novo's Wegovy pill ...

FDA approves Novo Nordisk's weight-loss pill Novo aims to regain market share from Eli Lilly Pill broadens potential patient pool The pill is 25 milligrams of semaglutide, the same active ingredient ...

Monte Rosa’s MRT-8102 Phase 1 shows deep NEK7 degradation and strong hsCRP drops; plus $200M raise extends runway. Learn more ...

The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy, the first daily oral medication for obesity treatment. The once-daily tablet — ...